

รายการอ้างอิง

1. Statistical unit, Faculty of Medicine, King chulalongkorn memorial hospital, Chulalongkorn university. **Tumour Registry Statistical Report**. 1985-1997.
2. Voravud N. Cancer in the Far East. In: Sikora K, Keith HE, eds. **Treatment of Cancer**. (2nd ed). London, Chapman and Hall Med 1990; 887-594.
3. Neel HB III, Pearson GR, Wei land LH. Anti EBV serologic test for nasopharyngeal carcinoma. **Laryngoscope** 1980; 90:1981-90.
4. Moore SB, Pearson GR, Neel HB III. HLA and nasopharyngeal carcinoma in North America Caucasoids. **Tissue Antigens** 1983; 22:72-5.
5. Huang DP, LoKW, Van Hasselt CA. A region of homozygous deletion on chromosome 9p21-21 in primary nasopharyngeal carcinoma. **Cancer Res** 1994; 54:4003.
6. Mutirangura A, Tanunyutthawongese C, Pornthanakasem W. Genomic alteration in nasopharyngeal carcinoma: loss of heterozygosity and Epstein-Barr virus infection. **British Journal of Cancer** 1997; 76(6): 770-6.
7. Liggett WH., Sidransky JD. Role of the p16 tumor suppressor gene in cancer. **J Clin Oncol** 1998; 16; 1197-206.
8. Salgia R, Skarin AT. Molecular abnormalities in lung cancer. **J Clin Oncol** 1998; 16;1207-17.
9. อภิวัฒน์ มุทิตรางกูร. Human gene & genome: stucture, mutation & analysis. ใน : นเรศ สุขเจริญ, อภิวัฒน์ มุทิตรางกูร, ยง ภู่วรรณ บรณาธิการ. **อณูชีววิทยาทางการแพทย์**. กรุงเทพฯ: บริษัท เท็กซ์ แอนด์ เจอร์นัล พับลิเคชั่น จำกัด 2541; 19-37.
10. Gazzeri S, Gouyer V, Vour'ch C, Brambilla C, Brambilla E. Mechanisms of p16INK4A inactivation in non small-cell lung cancers. **Oncogene** 1998; 29; 16: 497-504.
11. Taga S, Osaki T, Ohgami A, Imoto H, Yoshimatsu T, Yoshino I, et al. Prognostic value of the immunohistochemical detection of p16ink4 expression in non-small cell lung carcinoma. **Cancer** 1997; 80: 389-95.
12. Volm M, Koomagi R, Mattern J. Prognostic value of p16INK4A expression in lung adenocarcinoma. **Anticancer Res** 1998; 18: 2309-12.

13. Minobe K, Onda M, Lida A, Kasumi F, Sakamoto G, Nakamura Y, et al. Allelic loss on chromosome 9q is associated with lymph node metastasis of primary breast cancer. **Jpn J Cancer Res** 1998; 89: 916-22.
14. Takeuchi H, Ozawa S, Ando N, Shih CH, Koyanagi K, Ueda M, et al. Altered p16/MTS1/CDKN2 and cyclin D1/PRAD-1 gene expression is associated with the prognosis of squamous cell carcinoma of the esophagus. **Clin Cancer Res** 1997;3: 229-36.
15. Lydiatt WM, Davidson BJ, Schantz SP, Caruana S, Chaganti RS. 9p21 deletion correlates with recurrence in head and neck cancer. **Head Neck** 1998; 20:113-8.
16. Sparrow LE, Eldon MJ, English DR, Heenan PJ. P16 and p21WAF1 protein expression in melanocytic tumors by immunohistochemistry. **Am J Dermatopathol** 1998; 20: 55-61.
17. Hui AM, Sakamoto M, Kanai Y, Ino Y, Gotoh M, Yokota J, et al. Inactivation of p16INK4 in hepatocellular carcinoma. **Hepatology** 1996; 24: 575-9.
18. Hu YX, Watanabe H, Ohtsubo K, Yamaguchi Y, Ha A, Okaai T, et al. Frequent loss of p16 expression and its correlation with clinicopathological parameters in pancreatic carcinoma. **Clin Cancer Res** 1997; 3:1473-77.
19. Naka T, Kobayashi M, Ashida K, Totota N, Kaneko T, Kaibara N. Aberrant p16/INK4 expression related to clinical stage and prognosis in patients with pancreatic cancer. **Int J Oncol** 1998; 12: 1111-6.
20. Fleming ID, Cooper JS, Henson DE, Hutter RVP, Kennedy BJ, Murphy GP, et al. Nasopharynx In: **AJCC Cancer Staging Manual**, fifth edition. Philadelphia: Lippincott-Raven Publishers; 1997: 97-101.
21. Lo KW, Huang DP, Lau KM. P16 gene alterations in nasopharyngeal carcinoma. **Cancer Res** 1995; 55(10): 2039-43.
22. Gullley ML, Nicholls JM, Schneider BG, Amin MB, Ro JY, Geraldts J. Nasopharyngeal carcinomas frequently lack the p16/MTS1 tumor suppressor protein but consistently express the retinoblastoma gene product. **Am J Pathol** 1998; 152(4): 865-9.
23. Lo KW, Cheung ST, Leung SF, van Hasselt A, Tsang YS, Mak KF, et al. Hypermethylation of the p16 gene in nasopharyngeal carcinoma. **Cancer Res** 1996; 56(12): 2721-5.
24. Miracca EC, Kowalski LP, Nagai MA. High prevalence of P16 gene alterations in head and neck tumours. **Br J Cancer** 1999; 81(4): 677-83.

25. Nuovo GJ, Plaia TW, Belinsky SA, Baylin SB, Herman JG. In situ detection of the hypermethylation-induced inactivation of the p16 gene as an early event in oncogenesis. *Proc Natl Acad Sci USA* 1999; 96(22):12754-9.
26. นรินทร์ วรรณดี. Cancer biology. ใน: วิชา ศรีดามา บรรณาธิการ. ตำราอายุรศาสตร์ 2. กรุงเทพฯ: โรงพิมพ์ศูนย์ดี พับลิเคชั่น 2538; 573-602.
27. Charuruks N, Voravud N. Molecular biology of head and neck tumorigenesis: The role of p53 expression and genetic instability. *J Med Assoc Thai* 1996; 79: 83-9.
28. นวพรรณ จารุรักษ์. The role of cell-cycle and apoptosis in tumorigenesis. ใน: นเรศ สุขเจริญ, อภิวัฒน์ มุทิตางกูร, ยง ภู่วรรณ บรรณาธิการ. *อณูชีววิทยาทางการแพทย์*. กรุงเทพฯ: บริษัท เท็กซ์ แอนด์ เจอร์นัล พับลิเคชั่น จำกัด 2541; 447-62.
29. Charuruks N, Sutheesophon J, Voravud N. Cell cycle and tumorigenesis. *Chula Med J* 1998; 42(11): 1035-48.
30. Benchimol S, Minden MD. Viruses, oncogenes, and tumor suppressor genes. In: Tannock LF, Hill RP. *The basic science of oncology*, third edition. Singapore : McGraw-Hill 1998;79-105.
31. Kautiainen TL, Jones PA: DNA methyltransferase levels in tumorigenic and nontumorigenic cells in culture. *J Biol Chem* 1986; 261:1594.
32. Issa JP, Vertino PM, Wu J, Sazawal S, Celano P, Nelkin BD, et al. Increased cytosine DNA-methyltransferase activity during colon cancer progression. *J Natl Cancer Inst* 1993; 85:1235.
33. Laird PW, Jackson-Grusby L, Fazeli A, Dickinson SL, Jung WE, Li E, et al. Suppression of intestinal neoplasia by DNA hypomethylation. *Cell* 1995; 81: 197.
34. Baylin SB, Herman JG, Graff JR, Vertino PM, Issa JP: Alterations in DNA methylation: A fundamental aspect of neoplasia. *Adv Cancer Res* 1998; 72:141.
35. Laird PW, Jaenisch R: The role of DNA methylation in cancer genetic and epigenetics. *Ann Rev Genet* 1996; 30: 441.
36. Coulondre C, Miller JH, Farabaugh PJ, Gilbert W: Molecular basis of base substitution hotspots in *Escherichia coli*. *Nature* 1978; 274: 775.
37. Gonzalgo ML, Liang G, Spruck CHr, Zingg JM, Rideout WMr, Jones PA: Identification and characterization of differentially methylated regions of genomic DNA by methylation-sensitive arbitrarily primed PCR. *Cancer Res* 1997; 57: 594.

38. Bender CM, Zingg JM, Jones PA: DNA methylation as a target for drug design. **Pharmaceutical Res** 1998; 15: 175.
39. Greenblatt MS, Bennett WP, Hollstein M, Harris CC: Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis. **Cancer Res** 1994; 54: 4855.
40. Magewu AN, Jones PA: Ubiquitous and tenacious methylation of the CpG site in codon 248 of the p53 gene may explain its frequent appearance as a mutational hot spot in human cancer. **Mol Cell Biol** 1994; 14: 4225.
41. Gama-Sosa MA, Slagel VA, Trewyn RW, Oxenhandler R, Kuo KC, Gehrke CW, et al. The 5-methylcytosine content of DNA from human tumors. **Nucleic Acids Res** 1983;11: 6883.
42. Christman JK, Sheikhnejad G, Dizik M, Abileah S, Wainfan E: Reversibility of changes in nucleic acid methylation and gene expression induced in rat liver by severe dietary methyl deficiency. **Carcinogenesis** 1993; 14: 551.
43. Pogribny IP, Miller BJ, James SJ: Alterations in hepatic p53 gene methylation patterns during tumor progression with folate/methyl deficiency in the rat. **Cancer Lett** 1997; 115: 31.
44. Hanada M, Delia D, Aiello A, Stadtmauer E, Reed JC: bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia. **Blood** 1993; 82:1820.
45. Feinberg AP, Vogelstein B: Hypomethylation distinguishes genes of some human cancers from their normal counterparts. **Nature** 1983; 301: 89.
46. Greger V, Debus N, Lohmann D, Hopping W, Passarge E, Horsthemke B: Frequency and parental origin of hypermethylated RB1 alleles in retinoblastoma. **Hum Genet** 1994; 94: 491.
47. Sakai T, Toguchida J, Ohtani N, Yandell DW, Rapaport JM, Dryja TP: Allele-specific hypermethylation of the retinoblastoma tumor-suppressor gene. **Am J Hum Genet** 1991; 48: 880.
48. Ohtani-Fujita N, Fujita T, Aoike A, Osifchin NE, Robbins PD, Sakai T: CpG methylation inactivates the promoter activity of the human retinoblastoma tumor-suppressor gene. **Oncogene** 1993; 8:1063.

49. Gnarr JR, Tory K, Weng Y, Schmidt L, Wei MH, Li H, et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. **Nat Genet** 1984; 7: 85.
50. Herman JG, Latif F, Weng Y, Lerman MI, Zbar B, Liu S, et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. **Proc Natl Acad Sci USA** 1994; 91:9700.
51. Liggett WH Jr, Sidransky D: Role of the p16 tumor suppressor gene in cancer. **J Clin Oncol** 1998;16:1197-1206.
52. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, et al. 5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. **Nat Med** 1995; 1: 686.
53. Herman JG, Merlo A, Mao L, Lapidus RG, Issa JP, Davidson NE, et al. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. **Cancer Res** 1995; 55: 4525.
54. Cairns P, Polascik TJ, Eby Y, Tokino K, Califano J, Merlo A, et al. Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. **Nat Genet** 1995; 11:210.
55. Hannon GJ, Beach D: p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest. **Nature** 1994; 371: 257.
56. Uchida T, Kinoshita T, Nagai H, Nakahara Y, Saito H, Hotta T, et al. Hypermethylation of the p15INK4B gene in myelodysplastic syndromes. **Blood** 1997; 90:1403.
57. Ng MH, Chung YF, Lo KW, Wickham NW, Lee JC, Huang DP: Frequent hypermethylation of p16 and p15 genes in multiple myeloma. **Blood** 1997; 89: 2500.
58. Lengauer C, Kinzler KW, Vogelstein B: DNA methylation and genetic instability in colorectal cancer cells. **Proc Natl Acad Sci USA** 1997; 94:2545.
59. Jones PA, Gonzalgo ML: Altered DNA methylation and genome instability: A new pathway to cancer? **Proc Natl Acad Sci USA** 1997; 94:2103.
60. Chen RZ, Pettersson U, Beard C, Jackson-Grusby L, Jaenisch R: DNA hypomethylation leads to elevated mutation rates. **Nature** 1998; 395: 89.
61. Feinberg AP, Gehrke CW, Kuo KC, Ehrlich M: Reduced genomic 5-methylcytosine content in human colonic neoplasia. **Cancer Res** 1988; 48: 1159.

62. Oneill RJW, Oneill MJ, Graves JAM: Undermethylation associated with retroelement activation and chromosome remodelling in an interspecific mammalian hybrid. **Nature** 1998; 393: 68.
63. Singal R, Ginder GD: DNA Methylation. **Blood** 1999; 93: 4059-4070.
64. Neel HB III. Nasopharyngeal carcinoma: Diagnosis Staging, and Management. **Oncology** 1992; 6(2): 87-95.
65. Shanmugaratnam K, Sobin LH. Histological typing of upper respiratory tract tumors. In: **International histological classification of tumors**, No 19. Geneva, World Health Organization, 1978.
66. Neel HB III, Taylor WF. Epstein-Barr virus-related antibody: Changes in titers after therapy for nasopharyngeal carcinoma. **Arch Otolaryngol Head Neck Surg** 1990; 116: 1287-1290.
67. Tanunythawongse C, Mutirangura A, Voravud N. Molecular diagnosis of Epstein-Barr viral (EBV) genome in Thai patients with nasopharyngeal carcinoma. **Proceeding 36th Annual Scientific Meeting, Chulalongkorn University Hospital** 1995, 171-172.
68. Chow WH, McLaughlin JK, Hrubec Z. Tobacco use and nasopharyngeal carcinoma in a cohort of US veterans. **Int J Cancer** 1993; 55: 539-540.
69. Mutirangura A, Voravud N, Sriuranpong V. Loss of heterozygosity in oncogenesis of nasopharyngeal carcinoma. **Proceeding 11th Annual Meeting, Royal College of Thai Physician** 1995,105.
70. Trivedi P, Hu lf, Bhen F. Epstein-Barr virus-encoded membrane protein LMP1 from a nasopharyngeal carcinoma is non-immunogenic in a murine model system, in contrast to a B cell-derived homologue. **Eru J Cancer** 1994; 30: 84-88.
71. Dawson CW, Rickinson AB, Young LS. Epstein-Barr virus latent membrane protein inhibits human epithelial cell differentiation. **Nature** 1990; 334: 777-780.
72. Senba M, Zhong XY, Itakora H. EBNA2 expression in nasopharyngeal carcinoma. **Hum Pathol** 1994; 25: 327-328.
73. Lu OL, Elia G, Lucas S. Bcl-2 proto-oncogene expression in Epstein-Barr virus-associated nasopharyngeal carcinoma. **Int J Cancer** 1993; 53: 29-35.
74. Hsu MM, Huang Sc, Lynn TC. The survival of patients with nasopharyngeal carcinoma. **Otolaryngol Head Neck Surg** 1982; 90: 289-295.

75. Zheng Ym, Tuppin P, Hubert Al. Environmental and dietary risk factors for nasopharyngeal carcinoma: a case-control study in Zangwu Country, Guangxi China. **Br J Cancer** 1994; 69: 508-514.
76. Leibowitz D. Nasopharyngeal carcinoma: the Epstein-Barr virus association. **Semin Oncol** 1994; 21: 376-381.
77. Burt RD, Vaughan TL, Nixperos B. A prospective association between the HLA-A2 antigen and nasopharyngeal carcinoma in US whites. **Int J Cancer** 1994; 56: 465-467.
78. Moore SB, Pearson GR, Neel HB III. HLA and nasopharyngeal carcinoma in North America Caucasoids. **Tissue Antigens** 1983; 22: 72-75.
79. Lertsanguansinchai P, Thithathan S, Rojpornpradit P. Nasopharyngeal carcinoma (NPC): a retrospective review of 184 patients treated with radiotherapy. **Chula Med J.**1992, 36(II): 830-837.
80. Shantz SP, Harrison LB, Hong WK. Cancer of the Head and Neck. In: DeVita VT, Jr Hellman S, Rosenberg SA, eds. **Cancer: Principles and Practice of Oncology** (4th ed). Philadelphia, J.B. Lippincott. 1993, 574-672.
81. Neele HB III. Nasopharyngeal carcinoma: Clinical Presentation, diagnosis, treatment and prognosis. **Otolaryngol Clin North Am** 1985; 18: 479-490.
82. Skinner SW, Van Hasselt CA, Tsao SY. Nasopharyngeal carcinoma: modes of presentation. **Ann Otol Rhinol laryngol** 1991; 100: 544-551.
83. Greco FA, Hainworth J D. Cancer of Unknown Primary Site. In: DeVita VT, Hellman S, Rosenberg SA. **Cancer: Principles & Practice of Oncology** (4th ed). Philadelphia, J.B. Lippincott 1993,2072-2092.
84. Cvitkovic E, Bachouchi M, boussen H. Leukemoid reaction, bone marrow invasion, fever of unknown origin, and metastatic pattern in the natural history of undifferentiated carcinoma of nasopharyngeal type: a review of 255 consecutive case. **J Clin Oncol** 1993; 11: 2434-2442.
85. Fandi A, Cvitkovic E. Biology and treatment of nasopharyngeal cancer. **Oncology** 1995;7: 255-263.
86. Wei EI, Sham JST, Zong YS. The efficacy of fiberoptic endoscopic examination and biopsy in the detection of early nasopharyngeal carcinoma. **Cancer** 1991; 67: 3127-3130.

87. Skinner SW, Van Hasselt CA, Tsao SY. Nasopharyngeal carcinoma: modes of presentation. **Ann Otol Rhinol Laryngol** 1991; 100: 544-551.
88. Shahab. I, Osborne B, Butler J. Nasopharyngeal lymphoid tissue masses in patients with human immunodeficiency virus-I. **Cancer** 1994; 74: 3083-88.
89. Cheung YK, Sham J, Cheung YL. Evaluation of skull base erosion in nasopharyngeal carcinoma: comparison of plain radiography and computed tomography. **Oncology** 1994; 51: 42-46.
90. Sham JST, Caheng YK, Choy D. Nasopharyngeal carcinoma: CT evaluation of patterns of tumor spread. **AJNR Am J Neuroradiol** 1991; 12: 265-270.
91. Mendelhall WM, Million RR, Mancuso AA. nasopharynx. IN: Million RR, Cassini NJ, eds. **Neck Cancer; A Multidisciplinary Approach**. Philadelphia, J.B. Lippincott. 1994; 599-626.
92. Mathew A, Cheng JM, Sam CK, Joab I, Prasad U, Cochet C: A high incidence of serum IgG antibodies to the Epstein-Barr virus replication activator protein in nasopharyngeal carcinoma. **Cancer Immunol Immunother** 1994; 38: 68-70.
93. Joab I, Triki H, de Saint-Martin J, Perricaudet M, Nicolas JC: Detection of anti-Epstein-Barr virus trans-activator (ZEBRA) antibodies in serum from patients with human immunodeficiency virus. **J Inf Dis** 1991; 163: 53-56.
94. Rousselet G, Bachouchi M, Busson P, Deveathaire F, Wasasugi H, Schwaab G et al. Clinical implication of the serum level of CD23 on patients with undifferentiated nasopharyngeal carcinoma. **J Clin Oncol** 1993; 11: 2143-2149.
95. Lai KN, Ho S, Leung JCK, Tsao SY: Soluble interleukin-2 receptors in patients with nasopharyngeal carcinoma. **Cancer** 1991; 67: 2180-2185.
96. Wolf GT, Wolfe RA: Circulating immune complexes in patients with nasopharyngeal carcinoma. **Laryngoscope** 1990; 100: 302.
97. Hauqing K, Minghuang H, Jun M, Enpi Z, Zixiang Z, Jin Z, et al. New staging system for nasopharyngeal carcinoma in Canina. **Int J Radiat Oncol Biol Phys** 1994; 30:1037-1042.
98. Shiu W, Leung SF, Leung Wt, Ho S, Tao M: Expression of B2-microglobulin by nasopharyngeal carcinoma. **Br J Cancer** 1992; 66:555-557.

99. Ho JH. Stage classification of nasopharyngeal carcinoma. A review. **IARC Sci Publ** 1978; 20:99-113.
100. Dickson R I. Nasopharyngeal carcinoma: An evaluation of 209 patients. **Laryngoscope** 1981; 91: 333-354.
101. Wen-Zhan C, dao-Lan Z, Ke-Shen L. Long term observation after radiotherapy for nasopharyngeal carcinoma (NPC). **Int J Radiat Oncol Biol Phys** 1989; 16: 311-314.
102. Mesic JB, Fletcher GH, Goepfert H. Megavoltage irradiation of epithelial tumors of the nasopharynx. **Int J Radiat Oncol Biol Phys** 1981; 7: 447-453.
103. Neel HB, Taylor WF; New staging system for nasopharyngeal carcinoma. **Arch Otolaryngol Head Neck Surg** 1989; 115: 1293-1303.
104. Huang S. Choy G. Nasopharyngeal cancer: Study II. **Int J Radiat Oncol Biol Phys** 1981;6: 713-716.
105. Huang S. Lui L, Lynn T. Nasopharyngeal cancer: Study IV A review of 1206 patients treated with combined modalities. **Int J Radiat Oncol Biol Phys** 1985; 10: 1789-1793.
106. Rahima M, rakowsky E, Barzilay J. Carcinoma of the nasopharynx. An analysis of Cancer 91 cases and a comparison of differering treatment approaches. **Cancer** 1986;58: 843-849.
107. Tsujii H, Kamada T, Tsujii H. Improved results in the treatment of nasopharyngeal carcinoma using combined radiotherapy and chemotherapy. **Cancer** 1989; 63: 1668-1672.
108. Tannock I, Payne D, Cummings B. Sequential chemotherapy and radiation for nasopharyngeal cancer: Absence of long-term benefit despite high rate of tumor response to chemotherapy. **J Clin Oncol** 1987; 4: 629-634.
109. Rossi A Molinari r, Boracchi . Adjuvant chemotherapy with vincristine, cyclophosphamide and adriamycin (VCA) after local-regional radiotherapy in nasopharyngeal carcinoma: Result of a 4-years multicentric randomized study. **J Clin Oncol** 1988; 6: 1401-1410.

110. Al-Sarraf M, Pajak Tf, Cooper JS. Chemo-radiotherapy in patients with locally advanced nasopharyngeal carcinoma: A Radiation Therapy Oncology Group Study. **J Clin Oncol** 1990; 8(8): 1342-1351.
111. Crottes EP, Kalra J, Amin VC. Chemotherapy for head and neck cancer relapsing after chemotherapy. **Cancer** 1981; 47: 1966-1970.
112. Goepfert H, Moran ME, Lindberg RD: Chemotherapy of advanced nasopharyngeal carcinoma. **Proc Am Soc Clin Oncol** (abstr L-271) 1981; 22: 427.
113. Decker DA, Drelichman A, AL-Sarraf M. Chemotherapy for nasopharyngeal carcinoma: A ten year experience. **Cancer** 1983; 52: 602-605.
114. Al kourainy K, Crissman C, Ensley J. Excellent responses to cisplatin-based chemotherapy in patients with recurrent or previously untreated advanced nasopharyngeal carcinoma. **Am J Clin Oncol** 1988; 11: 427-430.
115. Schornagel JH, Verwij J, de Mulder NH. EORTC Head and neck Cancer Cooperative Group: Acute Blindness during treatment of recurrent or metastatic nasopharyngeal carcinoma with doxorubicin and CCNU. **Eur J Cancer** 1990; 26: 859.
116. Choo R, Tannock I: Chemotherapy for recurrent or metastatic carcinoma of the nasopharynx. A review of the Princess Margaret Hospital experience. **Cancer**.1991; 68: 2120-2124.
117. Marcenini S, Licitra L, Grandi L. Cisplatin and fluorouracil in recurrent and/or disseminated nasopharyngeal carcinoma. **Proc Am Soc Clin Oncol** 1991; 10: 202.
118. Cvitkovic E, Mahjoubi R, Lianes P. 5 Fluorouracil (FU), mitomycin (M),epirubicin (E), cisplatin (P) in recurrent and/ or metastatic undifferentiated nasopharyngeal carcinoma (UCNT). **Proc Am Soc Clin Oncol** 1991; 11: 240(abstr 664).
119. Boussen H, Cvitkovic E, Wendling JL. Chemothearpy of metastatic and /or recurrent undifferentiated nasopharyngeal carcinoma with cisplatin, bleomycin and fluorouracil. **J Clin. Oncol** 1991; 9: 1675-1681.
120. Mahjoubi R, Azli N, Bachouchi M. Metastatic undifferentiated carcinoma of nasopharyngeal type treated with bleomycin (B), Epirubicin (E), and cisplatin (C): Final report. **Proc Am Soc Clin Oncol** 1992; 11: 240 (abstr 772).

121. Gebbia V, Zerillo G, Restivo G. Chemotherapeutic treatment of recurrent and/ or metastatic nasopharyngeal carcinoma: A retrospective analysis of 40 cases. **Br J Cancer** 1993; 68: 191-194.
122. Johansen LV, Mettre M, Overgaard J: Carcinoma of the nasopharynx: analysis of treatment results in 167 consecutively admitted patients. **Head Neck** 1992; 14: 200-207.
123. Grandi C, Boracchi P, Mezzanotte G, Squadrelli M, Marubini E, Molinari R: Analysis of prognostic factors and proposal of a new classification for nasopharyngeal cancer. **Head Neck** 1990; 12: 31-40.
124. Perez CA, Devineni VR, Marcial-Vega V, Marks JE, Simpson JR, Kucik N: Carcinoma of the nasopharynx: factors affecting prognosis. **Int J Radiat Oncol Biol Phys** 1992; 23: 271-280.
125. Dean Martin WM, Shah KJ: Carcinoma of the nasopharynx in young patients. **Int J Radiat Oncol Biol Phys** 1994; 28: 991-999.
126. Kaasa S, Krangh-Jenson E, Bjordal K, Lund E, Evensen JF, Vermund H, et al. Prognostic factors in patients with nasopharyngeal carcinoma. **Acta Oncol** 1993; 32: 531-536.
127. Dimery IW, Peters LJ, Goepfert H, Morrison WH, Byers RM, Guillory C, et al. Effectiveness of combined induction chemotherapy and radiotherapy in advanced nasopharyngeal carcinoma. **J Clin Oncol** 1993; 11: 1919-1928.
128. Roychowhury DF, Tseng A, Ru KK. New prognostic factors in nasopharyngeal carcinoma. **Proceeding American Soc Clin Oncol** 1995; 229(Abtract 846).
129. Gallo O, Bianchi S, Giannini A, Gallina E, Libonati GA, Fini-Strochi O: Correlations between histopathological and biological findings in nasopharyngeal carcinoma and its prognostic significance. **Laryngoscope** 1991; 101: 487-493.
130. De Vathaire F, Sancho-garnier H, De The H, Pieddeluop C, Schwaab G, Ho JHC et al. Prognostic value of EBV markers in the clinical management of nasopharyngeal carcinoma (NPC): a multi-center follow-up study. **Int J Cancer** 1988; 42: 176-181.
131. Neel HB, Taylor WF; New staging system for nasopharyngeal carcinoma. **Arch Otolaryngol Head Neck Surg** 1989; 115: 1293-1303.
132. Sanchez-Cespedes M, Esteller M, Wu L. Gene promoter hypermethylation in tumors and serum of head and neck cancer patients. **Cancer Res** 2000; 60(4): 892-5.

133. Riese U, Dahse R, Fieleder W. Tumor suppressor gene p16 (CDKN2A) mutation status and promoter inactivation in head and neck cancer. **Int J Mol Med** 1999; 4(1): 61-5.
134. Tao J, Wu B, Fang W: Mutation and methylation of CDKN2 gene in head and neck carcinomas. **Zhonghua Bing Li Xue Za Zhi** 1997; 26(3): 152-4.
135. Gongalez MV, Pello MF, Lopez-Larrea C. Deletion and methylation of the tumor suppressor gene p16/CDKN2 in primary head and neck squamous cell carcinoma. **J Clin Pathol** 1997; 50(6): 509-12.
136. Martinez-Delgado B, Richart A, Garcia MJ. Hypermethylation of P16ink4a and P15ink4b genes as a marker of disease in the follow-up of non-Hodgkin's lymphomas. **Br J Hematol** 2000; 109(1): 97-103.
137. Navas IC, Ortiz-Romero PL, Villuendas R: p16 (INK4a) gene alterations are frequent in lesions of mycosis fungoides. **Am J Pathol** 2000; 156(5): 1565-72.
138. Nosaka K, Maeda M, Tamiya S, Sakai T, Mitsuya H, Matsuoka M: Increasing methylation of the CDKN2A gene is associated with the progression of adult T-cell leukemia. **Cancer Res** 2000; 60(4): 1043-8.
139. Kempster S, Phillips WA, Bandur-Hudson S, Thomas RJ, Dow C, Rockman SP: Methylation of exon 2 of p16 is associated with late stage oesophageal cancer. **Cancer Lett** 2000; 150(1): 57-62.
140. Shim YH, Kang GH, Ro JY: Correlation of p16 hypermethylation with p16 protein loss in sporadic gastric carcinomas. **Lab Invest** 2000; 80(5): 689-95.
141. Garcia JF, Villuendas R, Algara P. Loss of p16 protein expression associated with methylation of the p16 (INK4a) gene is a frequent finding in Hodgkin's disease. **Lab Invest** 1999; 79: 1453-9.
142. Nuovo GJ, Plaia TW, Belinsky SA, Baylin SB, Herman JG: In situ detection of the hypermethylation-induced inactivation of the p16 gene as an early event in oncogenesis. **Proc Natl Acad Sci USA** 1999; 96(22): 12754-9.
143. Kashiwabara K, Oyama T, Sano T, Fakura T, Nakajima T: Correlation between methylation status of the p16/CDKN2 gene and the expression of p16 and Rb proteins in primary non-small cell lung cancers. **Int J Cancer** 1998; 79(3): 215-20.

ภาคผนวก

แบบบันทึกการศึกษาวิจัย NPC

List no. _____

DNA no. _____

HN. _____

ชื่อ _____

อายุ _____ ปี เพศ _____ เชื้อชาติ _____

NPC biopsy	WHO type	1	2	3	unknown
------------	----------	---	---	---	---------

Stage	_____	T	_____	N	_____	M	_____
-------	-------	---	-------	---	-------	---	-------

1. time of 1st diagnosis _____
2. chief complaint _____
3. duration of symptoms before Dx _____
4. time of start treatment _____
5. type of treatment 1. radiation 2. chemo-radiation
3. _____
6. response 1.yes 2.no
7. type of response 1.CR 2.PR 3.NR
8. duration of response _____
9. recurrence 1.yes 2.no
10. time of recurrence _____
11. status 1.death 2.alive
12. time of death _____
12. time of last follow up _____

P16 Methylation	1.Positive	2.Negative
-----------------	------------	------------

serum EBV DNA	1.Positive	2.Negative
---------------	------------	------------

หมายเหตุ

ที่อยู่ _____

ประวัติผู้เขียนวิทยานิพนธ์

นายแพทย์ สมชัย ลิ้มปการณฺ์ เกิดเมื่อวันที่ 24 กรกฎาคม พุทธศักราช 2510 ภูมิลำเนาเป็นคนจังหวัดกรุงเทพมหานคร สำเร็จการศึกษาระดับปริญญาแพทยศาสตรบัณฑิตจาก คณะแพทยศาสตร์ ศิริราชพยาบาล มหาวิทยาลัยมหิดลในปีการศึกษา 2535 ปัจจุบันรับราชการใน ตำแหน่งอายุรแพทย์โรคเลือด ประจำอยู่ที่โรงพยาบาลศูนย์ (โรงพยาบาลพุทธชินราช) จังหวัด พิษณุโลก สังกัดกระทรวงสาธารณสุข และเป็นอาจารย์แพทย์พิเศษของคณะแพทยศาสตร์ มหาวิทยาลัยนเรศวร จังหวัดพิษณุโลก ปีพุทธศักราช 2542 ได้เข้าศึกษาต่อในหลักสูตรปริญญาวิทยาศาสตรมหาบัณฑิต สาขาอายุรศาสตร์(โรคมะเร็ง) ภาควิชาอายุรศาสตร์ คณะแพทยศาสตร์ จุฬาลงกรณ์มหาวิทยาลัย หลังจบการศึกษาจะกลับเข้าทำงานในตำแหน่งอายุรแพทย์โรคเลือดและโรคมะเร็งที่โรงพยาบาลพุทธชินราชต่อไป

